Co-Located Conference AgendasCellTech India 2015 | Current Trends in Antibody Drug Conjugates | 
Monday, 2 March 201508:00 | Registration | 09:00 | Inauguration | |
Plenary Session |
| | 09:15 |  | Keynote Presentation Biotech Industrial Process : How Science, Technology and Market Demand meet
Alain Bernard, Vice President, UCB Pharma SA, Belgium
This
presentation will highlight the Novel Strategies developed by Pharmaceutical
Industry to improve Manufacturing process. It will focus on the safe
implementation of Biotechnology Process changes along with maintaining product
quality and comparability which has eliminated concerns of lack of capacities.
Further, it will discuss the new challenges facing the industry with novel
product formats and novel therapy paradigms. |
| 10:15 | Coffee Break and Networking Session | |
SESSION 1: Cell Culturing Strategies and Cell Line Optimization/ Session Chair: Pravin Potdar |
| | 10:45 | Cell Culture Overview and Challenges in Upstream Process Development
Kriti Shukla, Principal Scientist, Biocon Research Limited, India
The talk will address the basics of cell culture and challenges that are
encountered during upstream process development (PD) and how that impacts the
development of a drug. This will cover important PD parameters such as approach
towards product quality, productivity, process platform and associated
challenges. | 11:25 | Development & Characterization of Glioma Stem Cell Lines and Application of these Cell Lines as a Tool for Screening Anticancer Activity
Padma Shastry, Scientist, National Centre for Cell Science, India
This
talk will discuss about development and establishment of primary cell lines and
cultures from High Grade Gliomas. Further, it will explain the development and
use of 3D- multicellular Spheroids (MCS) cultures and will highlight the
potential of these cell lines/cultures as models
for screening potential anticancer
compounds/agents. | 12:05 | Developing and Utilizing 3D Culture Systems for New Target Discovery/Cell Based Assays
Praveen Reddy, Scientific Manager, Biocon Ltd, India
This talk will discuss about the development of 3D Culture Systems along with its
advantages over 2D Culture Systems. In addition, this talk also highlights the
pharmacological studies of Drug Candidates for New Target Discovery. Further,
in this talk the necessity of High-Content Screening coupled with automation
will be emphasized. | 12:45 | Lunch Break and Networking Session | |
SESSION 2: Cell Based Assays in Biomedical Research/Session Chair: Jeremy Simpson |
| | 13:30 |  | Keynote Presentation Implementing Phenotypic Cell Based Assay and HCI in Translational Research! Choosing Right Tools for the Job.
Anthony Mitchell Davies, Director, Trinity College Dublin, Ireland
|
| 14:30 | Choosing the Right Cell-Based Assays for Drug Discovery
Suresh Juluri, Assistant Director, Jubilant Biosys Ltd. , India
In this talk, the broad target classes and their
appropriate cell based assays will be covered. It will also highlight the value
of Phenotypic Screening and importance of establishing target engagement in
primary cell types. Further, advantages and caveats of cellular assays will
also be discussed.
| |
SESSION 3: Advanced Cell Based Screening Techniques/Session Chair: David Hay |
| | 15:10 | Cell based Assays and Screening Technologies
Shahab Uddin, Technology Manager, Centre for Cellular and Molecular Platforms, India
This presentation will highlight model
assay system, advances in assay chemistries
and signal detection technologies to be considered when choosing cell-based
assays for automated systems. Further, it will discuss how these assay systems in
use for drug target validation and ADMET studies can provide more
representative responses to in-vivo conditions. In addition, it will
throw light on 3D Cultures along with their advantages.
| 15:50 |  | Keynote Presentation Cell-Based Assays and Screening Techniques: A User's Guide
Stephen Brown, RNAi Facility Screening Manager, Sheffield University, United Kingdom
This talk will lay emphasis on Cellular Assays Development
and the quality of screens. Also, various related facilities will be discussed
along with their merits and pitfalls. Further, in this talk data from number of
screens will be presented along with the metrics used. |
| 16:50 | Complex Cell- and Tissue-Based Model Systems for Phenotypic Drug Discovery - Investigating the Functional Role of the Tumor Microenvironment
Matthias Nees, Group Leader, University of Turku, Finland
In this talk, the goal of cell culture model system to
address tumor/stroma will be presented. The application of High Content
Screening approaches and automated image analysis software tools for identifying
critical cell-cell-interactions and Phenotypic Drug discovery will also be covered.
Further, complex organotypic assays will be discussed to understand may of the
dynamic functions of living tissues in vitro. | 17:30 | End of First Day of Conference |
Tuesday, 3 March 2015 |
SESSION 4: Advances in Cell Culture and Development/ Session Chair: Padma Shastry |
| | 09:00 |  | Keynote Presentation Genome-Wide High Content Screens of Cell Function and Behaviour
Jeremy Simpson, Vice Principal, University College Dublin, Ireland
In this presentation, genome-wide RNA interference and automated high
content screening microscopy will be discussed which helps in systematically
dissecting secretory, endocytic and retrograde pathways and quantifying the
relevance of all genes to them. Particularly, regulatory networks spanning each
of these pathways will be focussed. Further, the advantages of information obtained
from these screens will be covered. |
| 10:00 | Assay Miniaturization Strategies: Smaller and Cheaper Cell-Based Assays for HCA
Anthony Mitchell Davies, Director, Trinity College Dublin, Ireland
This talk will discuss regarding assay
miniaturization for large-scale High-Content Screening along with its
advantages and other related issues. | 10:40 | QbD Approaches in Cell Culture Process Development
Alain Bernard, Vice President, UCB Pharma SA, Belgium
In this
Presentation, various strategies and approaches for designing and developing
manufacturing processes will be discussed for optimization of quality of the
process and the product. In addition, it will also report and define process development
space based on a rigorous risk analysis. Further, various process parameters
and how they may affect product critical quality attributes will also be
covered. Finally, the remaining open issues and outcomes of this approach will
be presented. | 11:20 | Coffee Break and Networking Session | |
SESSION 5: Advances in Stem Cell Based Systems/ Session Chair: T R Raju |
| | 11:40 |  | Keynote Presentation Delivering Functional Hepatocytes from Pluripotent Stem Cells
David Hay, Chair of Tissue Engineering, MRC Centre for Regenerative Medicine, University of Edinburgh, United Kingdom
This Keynote Talk will
present the most recent advances in Stem Cell based Systems. It will emphasize
on various Differentiation procedures for Pluripotent Stem Cells and will also
discuss how Stem Cell derived hepatocytes are scalable and can metabolize
Drugs. |
| 12:40 | Identifying and Validating Cellular Targets of Cancer using Somatic Stem Cells
Prithi Rajan, Adjunct Faculty- Chemical Physiology, The Scripps Research Institute, United States of America
This
talk will discuss a couple of ideas where novel targets related to cancer,
specifically gliomas, are studied using somatic stem cells along with other
primary cultures. Neural and mesenchymal stem cells are used as
experimental paradigms to explore alternative activation of the Stat signalling
pathway, and potential interactions between cells within the tumor vis-à-vis
immune reactions. The use of stem cell technology to study the cancer and
stem cell states will also be discussed. | 13:20 | Lunch Break and Networking Session | 14:20 | Poster Evaluation | |
SESSION 6: Stem Cells and CTC Strategies for Cancer/ Session Chair: K P R Pramod |
| | 14:40 | | 15:40 | The ‘Stem’ Of Cancer Chemoresistance- Targeting Cancer Stem Cells via the Wnt-Beta Catenin Pathway
Sudha Warrier, Associate Professor, Manipal Institute of Regenerative Medicine, India
This presentation will explore the effect of the Wnt antagonist,
secreted EMT in CSCs in gliomas. It will also highlight how sFRP4 acts through
the Wnt- ß-Catenin and the Wnt- calcium pathways in inhibiting CSCs. Further,
it will discuss about designing better targeted strategies to improve
chemo-response and eventually eliminate glioblastoma CSCs. | 16:20 | Sensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 Inhibition
Venkatesha Venkatasubbaiah, Independent Consultant, Piramal Life Sciences Ltd, India
This Presentation
will focus on the how Chk1 Inhibition sensitizes Pancreatic Stem Cells and
Tumours to Gemcitabine. Further, it will also discuss about the finding how
Chk1-mediated DNA damage response was greater in stem cells than in non–stem
cells which makes Chk1 a potential
therapeutic target for improving pancreatic cancer therapy. | 17:00 | End of Conference |
|
.jpg)
Add to Calendar ▼2015-03-02 00:00:002015-03-03 00:00:00Europe/LondonCellTech India 2015CellTech India 2015 in Bangalore, IndiaBangalore, IndiaSELECTBIOenquiries@selectbiosciences.com
